Stay updated with breaking news from Daniel Clair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PROMISE II Trial Met Primary Endpoint Therapy Demonstrates 76% Limb Salvage in Patients with Chronic Limb-Threatening Ischemia Who Otherwise Faced Amputation LimFlow SA, a pioneer in the
LimFlow said new study results demonstrated statistically significant survival with its chronic limb-threatening ischemia (CLTI) treatment.
March 30, 2023—LimFlow SA, a developer of minimally invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), announced
/PRNewswire/ -- VESTECK, Inc. is proud to announce that another global Endovascular thought leader, Professor Michel Reijnen has agreed to join the VESTECK...
Malvern, Pa. (PRWEB) November 17, 2022 -- HMP Global’s 2023 International Symposium on Endovascular Therapy (ISET) is strengthening its position as the